With positive data on mRNA Covid vaccine, Sanofi sets its sights on other pathogens
French vaccine giant Sanofi announced positive results of a Phase 1/2 clinical trial of its first mRNA vaccine on Tuesday, saying the early findings with a Covid-19 vaccine give the company confidence to shift gears on its mRNA program to pursue vaccines for other pathogens. The first in its sights is an influenza vaccine Sanofi hopes to begin testing in clinical trials next year.
Sanofi will not be developing an mRNA Covid-19 vaccine, Thomas Triomphe, global head of vaccines, told STAT in an interview. By the time the company could bring a Covid mRNA vaccine through the authorization process, that market will have been saturated, he said.
